CRISPR Therapeutics AG (CRSP) Change in Acquisitions & Divestments (2020 - 2026)

CRISPR Therapeutics AG (CRSP) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $192.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 3.53% year-over-year to $192.8 million; the trailing twelve-month figure through Mar 2026 stood at $7.3 million (down 99.37% YoY), and the FY2025 full-year result was $702000.0, down 99.94% from the prior year.
• Change in Acquisitions & Divestments grew to $192.8 million in Q1 2026, from -$710.6 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $419.7 million in Q3 2022 to a low of -$710.6 million in Q4 2025.
• A 5-year average of $238.2 million and a median of $287.4 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• Across the five-year window, Change in Acquisitions & Divestments jumped 194.21% in 2022 and slumped 290.5% in 2025, its largest moves.
• Tracing CRSP's Change in Acquisitions & Divestments over 5 years: stood at $325.1 million in 2022, then declined by 11.57% to $287.4 million in 2023, then climbed by 29.77% to $373.0 million in 2024, then tumbled by 290.5% to -$710.6 million in 2025, then soared by 127.13% to $192.8 million in 2026.
• Business Quant data shows CRSP's Change in Acquisitions & Divestments at $192.8 million in Q1 2026, -$710.6 million in Q4 2025, and $214.9 million in Q3 2025.